Targeting L-Lactate Metabolism to Overcome Resistance to Immune Therapy of Melanoma and Other Tumor Entities

Abstract EN

Although immunotherapy plays a significant role in tumor therapy, its efficacy is impaired by an immunosuppressive tumor microenvironment.

A molecule that contributes to the protumor microenvironment is the metabolic product lactate.

Lactate is produced in large amounts by cancer cells in response to either hypoxia or pseudohypoxia, and its presence in excess alters the normal functioning of immune cells.

A key enzyme involved in lactate metabolism is lactate dehydrogenase (LDH).

Elevated baseline LDH serum levels are associated with poor outcomes of current anticancer (immune) therapies, especially in patients with melanoma.

Therefore, targeting LDH and other molecules involved in lactate metabolism might improve the efficacy of immune therapies.

This review summarizes current knowledge about lactate metabolism and its role in the tumor microenvironment.

Based on that information, we develop a rationale for deploying drugs that target lactate metabolism in combination with immune checkpoint inhibitors to overcome lactate-mediated immune escape of tumor cells.